Skip to Main Content

Amin Nassar, MD

Clinical Fellow

Contact Information

Amin Nassar, MD

Research Summary

Dr. Nassar's research work has emanated in >40 original articles. His work aims at identifying genomic biomarkers across ancestral populations with cancer.

Extensive Research Description

  • Along with his colleagues, Dr. Nassar showed in a study published in "Cancer Cell" that tumor-only sequencing overestimates TMB especially in non-Europeans and developed a methodology to recalibrate TMB calculation by ancestry. They also showed that TMB may not be a biomarker predictive of clinical benefit in non-Europeans.
  • Dr. Nassar described the prevalence of KRASG12C mutations across sex, race, and cancer types. This work was published in the “The New England Journal of Medicine”.
  • Dr. Nassar found that NGS calling for mismatch repair deficiency is more sensitive than IHC. He showed that the subset of patients with MMR-D missed by IHC and detected by NGS have similar outcomes to patients that are detected by IHC. He was the senior author of this work published in "Cancer Cell".
  • Dr. Nassar led a multicenter study shothat consolidation EGFR TKI offers superior PFS compared to durvalumab or observation among patients with unresectable stage III NSCLC treated with concurrent chemoradiation.
  • Along with his colleagues, Dr. Nassar identified differences in the germline landscape among continental ancestries with renal cell carcinoma.


Research Interests

Allergy and Immunology; Genetics, Population; Biomarkers, Tumor; Epigenomics

Selected Publications